Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.
Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.